Business Description
PharmaCorp Rx Inc
NAICS : 551112
SIC : 7215
ISIN : CA74373X1015
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 24.23 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.77 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 29.74 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.75 | |||||
9-Day RSI | 45.54 | |||||
14-Day RSI | 52.28 | |||||
6-1 Month Momentum % | 157.14 | |||||
12-1 Month Momentum % | 157.14 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 33.16 | |||||
Quick Ratio | 33.08 | |||||
Cash Ratio | 32.94 | |||||
Days Inventory | 102.66 | |||||
Days Sales Outstanding | 80.27 | |||||
Days Payable | 217.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -24.39 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 34.02 | |||||
Operating Margin % | -413.4 | |||||
Net Margin % | -383.16 | |||||
FCF Margin % | -246.39 | |||||
ROE % | -17.5 | |||||
ROA % | -16.47 | |||||
ROIC % | -145.17 | |||||
ROC (Joel Greenblatt) % | -420.28 | |||||
ROCE % | -17.99 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 130 | |||||
PB Ratio | 2.81 | |||||
Price-to-Tangible-Book | 2.95 | |||||
EV-to-EBIT | -45.5 | |||||
EV-to-EBITDA | -46.35 | |||||
EV-to-Revenue | 185.73 | |||||
EV-to-FCF | -83.43 | |||||
Price-to-Net-Current-Asset-Value | 3.1 | |||||
Price-to-Net-Cash | 3.1 | |||||
Earnings Yield (Greenblatt) % | -2.2 | |||||
FCF Yield % | -0.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
PharmaCorp Rx Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 0.291 | ||
EPS (TTM) (C$) | -0.023 | ||
Beta | 0 | ||
Volatility % | 161.72 | ||
14-Day RSI | 52.28 | ||
14-Day ATR (C$) | 0.062285 | ||
20-Day SMA (C$) | 0.6765 | ||
12-1 Month Momentum % | 157.14 | ||
52-Week Range (C$) | 0.21 - 0.875 | ||
Shares Outstanding (Mil) | 115.32 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
PharmaCorp Rx Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
PharmaCorp Rx Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
PharmaCorp Rx Inc Frequently Asked Questions
What is PharmaCorp Rx Inc(TSXV:PCRX)'s stock price today?
When is next earnings date of PharmaCorp Rx Inc(TSXV:PCRX)?
Does PharmaCorp Rx Inc(TSXV:PCRX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |